Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2022
- The Future of Generics
Advertise

Search

Search

Close

Trending

Emphasizing the patient voice in health technology assessments

13th World ADC London 2023

Publications: The unsung heroes quietly transforming patients’ lives

Integrated evidence generation 2.0: A strategy for every stakeholder

RSV vaccine race in balance as FDA sets May date for Pfizer decision

cabozantinib

Liver

Cancer/ News/ News/ Oncology

Ipsen’s Cabometyx recommended by NICE for previously treated HCC

Nicole Raleigh British Liver Trust, Cabometyx, cabozantinib, HCC, Ipsen, Liver cancer, NICE, UCL Cancer Institute 0 Comment

French drugmaker Ipsen’s Cabometyx (cabozantinib) has been recommended by the National Institute for Health and Care Excellence (NICE)

X

Ipsen’s Cabometyx recommended by NICE for previously treated HCC

https://pharmaphorum.com/news/ipsens-cabometyx-recommended-by-nice-for-previously-treated-hcc/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

Frontiers Health Steering Committee spotlight – Monique Levy

Frontiers Health Steering Committee spotlight – Monique Levy

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Most popular

Most Viewed

Pfizer/BioNTech strike back in Moderna COVID vaccine lawsuit
Little Summit Therapeutics spends big bucks to rebuild pipeline
GSK trumpets Jemperli vs Keytruda data in first-line NSCLC
US court throws out lawsuits alleging Zantac caused cancer
Evidence standard drawn up for digital therapeutics

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com